针对不可切除EGFR突变阳性第三阶段非小细胞肺癌的向治疗:新兴证据和未来前景

相关实验视频

Updated: Jul 8, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Terufumi Kato¹, Ignacio Casarini², Manuel Cobo³

¹Department of Thoracic Oncology, Kanagawa Cancer Center, Asahi Ward, Yokohama, Japan.

Lung cancer (Amsterdam, Netherlands)

|December 13, 2023

概括

对于EGFR突变的不可切除的第三阶段非小细胞肺癌 (NSCLC),不建议使用免疫治疗. 皮肤上生长因子受体-铁氨酸激酶抑制剂 (EGFR-TKI) 是有前途的,正在研究中.

科学领域:

在瘤学瘤学.
胸部外科手术胸部外科手术
医学遗传学医学遗传学

背景情况:

表皮生长因子受体 (EGFR) 突变发生在三分之一的不可切除的第三期非小细胞肺癌 (NSCLC) 患者中.
目前的标准护理包括巩固杜瓦卢马布 (PACIFIC疗法) 化学放射治疗后的治疗.
免疫治疗对EGFR突变阳性 (EGFRm) NSCLC的益处尚未明确,并未根据ESMO指南推使用.

研究的目的:

审查目前对不可切除EGFRmIII期NSCLC的管理.
概述在这种环境中研究EGFR-氨酸激酶抑制剂 (EGFR-TKI) 的理由.
讨论正在进行的临床试验和证据差距.

主要方法:

审查当前的文献和临床试验数据.
对EGFR-TKIs在不可切除EGFRmIII期NSCLC中的初步疗效信号的分析.
讨论证据缺口和未来的挑战.

主要成果:

EGFR-TKIs在转移性和早期切除性EGFRm NSCLC中显示出显著的益处.
初步数据表明,EGFR-TKI在不可切除的EGFRmIII期NSCLC中具有潜在的疗效.
目前正在进行几项临床试验,以评估EGFR-TKIs在这种特定患者群体中.

结论:

在不可切除EGFRmIII期NSCLC中EGFR-TKI的作用需要进一步的前性研究.
目前的证据表明,EGFR-TKIs可能为这个群体提供一种有前途的免疫疗法替代方案.
解决证据差距对于优化治疗策略至关重要.

关键词:

非小细胞肺癌,非小细胞肺癌.化学疗法或放射疗法在 Durvalumab 中使用.在ErbB受体中,免疫治疗是一种免疫疗法.突变突变是一种突变.蛋白质激酶抑制剂蛋白质激酶抑制剂

相关概念视频

02:57

Targeted Cancer Therapies

7.6K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.6K

02:38

Mitogens and the Cell Cycle

6.5K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

6.5K

02:50

Combination Therapies and Personalized Medicine

4.9K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...